Nucleai

Antibody-drug conjugate
#ADC #Antibodies #Antibody drug conjugate (ADC) #Cancer research #Collaboration #Gilead Sciences #Nucleai #Oncology

Nucleai and Gilead Sciences enter oncology ADC collaboration

Nucleai and Gilead Sciences have entered an ongoing translational research collaboration, supporting Nucleai’s global antibody-drug conjugate (ADC) clinical development programmes. Nucleai’s AI-powered platform analyses pathology images to provide quantitative insights into tissue biology. As part of its collaboration with Gilead, Nucleai has analysed a large dataset of hematoxylin and eosin… Read More

#News

#AI #Biomarkers #Clinical trials #Collaboration #Digital biomarkers #Nucleai #Precision medicine #Proscia

Proscia teams up with Nucleai to improve access to AI biomarkers

Software company Proscia has partnered with spatial AI biomarker company Nucleai in a collaboration aimed at improving precision medicine biomarkers for clinical trials.   The companies are integrating Nucleai’s predictive biomarker solutions into Proscia’s Concentriq software platform and will make them available as part of Proscia’s precision medicine… Read More

#Business & Investment #News